Since therapeutic doses and the schedule of selenium partially downregulate the expression levels of VEGF in tumor cells expressing HIF1α but not HIF2α [20,23], we propose, therefore, adding TKI inhibitors to the combination regimen in order for maximum downregulation of VEGF/VEGFR. Here, EPAS1 is linked to neoplasm.